Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Neoplasm Metastasis 1Breast Neoplasms 1Breast Diseases 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Specimen Handling 258Magnetic Resonance Spectroscopy 213pembrolizumab 202Carboplatin 170Cisplatin 137Biopsy 133Cyclophosphamide 130Paclitaxel 120Nivolumab 109Gemcitabine 102Bevacizumab 102Radiotherapy 81Dexamethasone 77Pemetrexed 75atezolizumab 71Fluorouracil 71fludarabine 68Doxorubicin 67Leucovorin 66Docetaxel 65Radiation 64Oxaliplatin 62Rituximab 60venetoclax 58Prednisone 57Cetuximab 54durvalumab 53Vincristine 52Etoposide 51130-nm albumin-bound paclitaxel 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × taxane × 30 days × Clear all
NCT07578116 2026-05-27

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

SWOG Cancer Research Network

Phase 3 Not yet recruiting
562 enrolled
Breast

Anatomic Stage IV Breast Cancer AJCC v8

NCT04784715 2026-05-22

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

AstraZeneca

Phase 3 Active not recruiting
1,157 enrolled 1 FDA
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡